BioPharmSignal logoBioPharmSignal

Biotech News

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Immuneering (IMRX)ImmuneeringEarnings

- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer now

Open original release

Related news

IMRXImmuneering2026-06-01 11:30 EST

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

IMRXImmuneering2026-05-21 21:00 EST

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

FATEFate Therapeutics2026-05-13 12:30 EST

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

ERASErasca2026-05-11 20:01 EST

Erasca Reports First Quarter 2026 Business Updates and Financial Results

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

KURAKura Oncology2026-05-12 20:02 EST

Kura Oncology Reports First Quarter 2026 Financial Results

View all latest news

Immuneering

Immuneering is an oncology company focused on deep pathway inhibition and precision cancer medicine. Its development strategy is centered on targeting signaling networks that drive tumor growth.

Recent company news

IMRXImmuneering2026-06-01 11:30 EST

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

IMRXImmuneering2026-05-21 21:00 EST

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

IMRXImmuneering2026-05-15 11:35 EST

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

IMRXImmuneering2026-04-21 20:05 EST

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

IMRXImmuneering2026-04-20 13:00 EST

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Stock data

Close
4.24 USD
Market cap
276.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States